Bisphosphonate-induced orbital inflammation: more common than once thought?

Curragh, David; Selva, Dinesh

doi:10.1007/s00198-019-04850-w

Cited by 14 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, oral systemic corticosteroids alone or following an intravenous corticosteroid cycle are the treatment of choice, with excellent results in 72% of the patients. [31] The response was effective in all cases; symptoms and CT scan or MRI findings showed complete resolution when the treatment was started seasonally. Delays in treatment are associated with an increased risk of complications.…”

Section: Discussionmentioning

confidence: 83%

Orbital Inflammation Caused by Aminobisphosphonates

Barlatay

Boza

Gauna

et al. 2022

JOVR

View full text Add to dashboard Cite

The aim of this review was to describe orbital inflammation secondary to aminobisphosphonates by analyzing demographic data, clinical presentation, and treatment of the disease. This is a narrative literature review. The search was performed using databases such as Ovid/MEDLINE and COCHRANE. The searches were limited to papers in the English language. We found 43 cases of orbital inflammation due to aminobisphosphonates. Zoledronate was the drug most associated with orbital side effects. Clinical presentation was evident by unilateral involvement (89%), palpebral edema (88%), conjunctival congestion (81%), chemosis (79%), ocular pain (77%), ocular motility impairment (65%), proptosis (56%), and blurred vision (39%). It can affect both eyes (11%) and is accompanied by anterior uveitis (23%). Orbital inflammation secondary to aminobisphosphonates is a severe side effect. Clinically, it cannot be distinguished from idiopathic inflammation of the orbit. Therefore, it is important to rule out previous drug exposure. Timely treatment is vital to expect a favorable outcome, with systemic corticosteroids being the treatment of choice.

show abstract

Section: Discussionmentioning

confidence: 83%

Orbital Inflammation Caused by Aminobisphosphonates

Barlatay

Boza

Gauna

et al. 2022

JOVR

View full text Add to dashboard Cite

show abstract

“…Bisphosphonates, also known as osteoclast-inhibiting agents, are mainly used for bone-resorbing clinical conditions such as osteoporosis [43]. The association of aminobiphosphonates with NSOI could be attributable to their structural homology with the ligand socket of γδ T cells, therefore leading to T cell activation and inflammatory mediator release [44][45][46][47].…”

Section: Environmental Factorsmentioning

confidence: 99%

Nonspecific Orbital Inflammation (NSOI): Unraveling the Molecular Pathogenesis, Diagnostic Modalities, and Therapeutic Interventions

Wu,

Kulbay,

Daigle

et al. 2024

IJMS

View full text Add to dashboard Cite

Nonspecific orbital inflammation (NSOI), colloquially known as orbital pseudotumor, sometimes presents a diagnostic and therapeutic challenge in ophthalmology. This review aims to dissect NSOI through a molecular lens, offering a comprehensive overview of its pathogenesis, clinical presentation, diagnostic methods, and management strategies. The article delves into the underpinnings of NSOI, examining immunological and environmental factors alongside intricate molecular mechanisms involving signaling pathways, cytokines, and mediators. Special emphasis is placed on emerging molecular discoveries and approaches, highlighting the significance of understanding molecular mechanisms in NSOI for the development of novel diagnostic and therapeutic tools. Various diagnostic modalities are scrutinized for their utility and limitations. Therapeutic interventions encompass medical treatments with corticosteroids and immunomodulatory agents, all discussed in light of current molecular understanding. More importantly, this review offers a novel molecular perspective on NSOI, dissecting its pathogenesis and management with an emphasis on the latest molecular discoveries. It introduces an integrated approach combining advanced molecular diagnostics with current clinical assessments and explores emerging targeted therapies. By synthesizing these facets, the review aims to inform clinicians and researchers alike, paving the way for molecularly informed, precision-based strategies for managing NSOI.

show abstract

Idiopathische Orbitaentzündung (IOE) (engl. idiopathic orbital inflammation [IOI], idiopathic orbital inflammation syndrome [IOIS], nonspecific orbital inflammation [NSOI], orbital inflammatory syndrome [OIS])

Nölle¹,

Both²

2021

Entzündliche Augenerkrankungen

View full text Add to dashboard Cite

Bisphosphonate-induced orbital inflammation: more common than once thought?

Cited by 14 publications

References 18 publications

Orbital Inflammation Caused by Aminobisphosphonates

Orbital Inflammation Caused by Aminobisphosphonates

Nonspecific Orbital Inflammation (NSOI): Unraveling the Molecular Pathogenesis, Diagnostic Modalities, and Therapeutic Interventions

Idiopathische Orbitaentzündung (IOE) (engl. idiopathic orbital inflammation [IOI], idiopathic orbital inflammation syndrome [IOIS], nonspecific orbital inflammation [NSOI], orbital inflammatory syndrome [OIS])

Contact Info

Product

Resources

About